Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Hurvitz, SA; Martin, M; Press, MF; Chan, D; Fernandez-Abad, M; Petru, E; Rostorfer, R; Guarneri, V; Huang, CS; Barriga, S; Wijayawardana, S; Brahmachary, M; Ebert, PJ; Hossain, A; Liu, JG; Abel, A; Aggarwal, A; Jansen, VM; Slamon, DJ.

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2(-) Breast Cancer

CLINICAL CANCER RESEARCH. 2020; 26(3): 566-580 Nº de citas: 195 [doi:10.1158/1078-0432.CCR-19-1425]

Rugo, HS; Ettl, J; Hurvitz, SA; Goncalves, A; Lee, KH; Fehrenbacher, L; Mina, LA; Diab, S; Woodward, NE; Yerushalmi, R; Goodwin, A; Blum, JL; Martin, M; Quek, RGW; Tudor, IC; Bhattacharyya, H; Gauthier, E; Litton, JK; Eiermann, W.

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

JNCI Cancer Spectrum. 2020; 4(1): Nº de citas: 25 [doi:10.1093/jncics/pkz085]

Jerez, Y; Marquez-Rodas, I; Aparicio, I; Alva, M; Mart?n, M; L?pez-Tarruella, S.

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

DRUGS. 2020; 80(2): 131-146 Nº de citas: 14 [doi:10.1007/s40265-019-01235-5]

Lazaro, M; Valderrama, BP; Suarez, C; de-Velasco, G; Beato, C; Chirivella, I; Gonzalez-Del-Alba, A; La?nez, N; M?ndez-Vidal, MJ; Arranz, JA.

SEOM clinical guideline for treatment of kidney cancer (2019)

Clinical & Translational Oncology. 2020; 22(2): 256-269 Nº de citas: 20 [doi:10.1007/s12094-019-02285-7]

Feliu, J; Garcia-Carbonero, R; Capdevila, J; Guasch, I; Alonso-Orduna, V; Lopez, C; Garcia-Alfonso, P; Castanon, C; Sevilla, I; Cerezo, L; Conill, C; Quintana-Angel, B; Sanchez, ME; Ghanem, I; Martin-Richard, M; Lopez-Gomez, M; Leon, A; Caro, M; Fernandez, T; Maurel, J.

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

Cancer Medicine. 2020; 9(3): 1008-1016 Nº de citas: 9 [doi:10.1002/cam4.2722]

Martin, AJM; Diaz, EG; Escobar, IG; Montero, RM; Martinez-Marin, V; Olmos, VP; Segura, PP; Verduguez, TQ; Fernandez, MS.

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

Clinical & Translational Oncology. 2020; 22(2): 171-186 Nº de citas: 44 [doi:10.1007/s12094-019-02263-z]

Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group).

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(3): 203-213 Nº de citas: 115 [doi:10.1200/JCO.19.00904]

Gerber, DE; Infante, JR; Gordon, MS; Goldberg, SB; Martin, M; Felip, E; Garcia, MM; Schiller, JH; Spigel, DR; Cordova, J; Westcott, V; Wang, YL; Shames, DS; Choi, Y; Kahn, R; Dere, RC; Samineni, D; Xu, J; Lin, KD; Wood, K; Royer-Joo, S; Lemahieu, V; Schuth, E; Vaze, A; Maslyar, D; Humke, EW; Burris, HA.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

CLINICAL CANCER RESEARCH. 2020; 26(2): 364-372 Nº de citas: 50 [doi:10.1158/1078-0432.CCR-18-3965]

Marin-Barrera, L; Muñoz-Martin AJ; Rios-Herranz, E; Garcia-Escobar, I; Beato, C; Font, C; Oncala-Sibajas, E; Revuelta-Rodriguez, A; Areses, MC; Rivas-Jimenez, V; Moreno-Santos, MA; Ballaz-Quincoces, A; Lopez-Saez, JB; Gallego, I; Elias-Hernandez, T; Asensio-Cruz, MI; Chasco-Eguilaz, L; Garcia-Gonzalez, G; Estevez-Garcia, P; Otero, R; Lima-Alvarez, J; Jara-Palomares, L.

A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study

Cancers. 2020; 12(1): Nº de citas: 25 [doi:10.3390/cancers12010075]

Aranda, E; Vieitez, JM; Gomez-Espana, A; Calle, SG; Salud-Salvia, A; Grana, B; Garcia-Alfonso, P; Rivera, F; Quintero-Aldana, GA; Reina-Zoilo, JJ; Gonzalez-Flores, E; Fernandez, MS; Guillen-Ponce, C; Garcia-Carbonero, R; Safont, MJ; Munoa, AL; Garcia-Paredes, B; Lopez, RL; Sastre, J; Diaz-Rubio, E.

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and >= 3 circulating tumour cells: the randomised phase III VISNu-1 trial

ESMO Open. 2020; 5(6): Nº de citas: 47 [doi:10.1136/esmoopen-2020-000944]

Coleman, R; Finkelstein, DM; Barrios, C; Martin, M; Iwata, H; Hegg, R; Glaspy, J; Perianez, AM; Tonkin, K; Deleu, I; Sohn, J; Crown, J; Delaloge, S; Dai, T; Zhou, Y; Jandial, D; Chan, A.

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

LANCET ONCOLOGY. 2020; 21(1): 60-72 Nº de citas: 204 [doi:10.1016/S1470-2045(19)30687-4]

Finn, RS; Liu, Y; Zhu, Z; Martin, M; Rugo, HS; Dieras, V; Im, SA; Gelmon, KA; Harbeck, N; Lu, DR; Gauthier, E; Bartlett, CH; Slamon, DJ.

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer

CLINICAL CANCER RESEARCH. 2020; 26(1): 110-121 Nº de citas: 161 [doi:10.1158/1078-0432.CCR-19-0751]

Lopez-Tarruella, S; Escudero, MJ; Pollan, M; Martin, M; Jara, C; Bermejo, B; Guerrero-Zotano, A; Garcia-Saenz, J; Santaballa, A; Alba, E; Andres, R; Martinez, P; Calvo, L; Fernandez, A; Batista, N; Llombart-Cussac, A; Anton, A; Lahuerta, A; de la Haba, J; Lopez-Vega, JM; Carrasco, E.

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

Scientific Reports. 2019; 9: Nº de citas: 16 [doi:10.1038/s41598-019-55765-9]

Álvarez Álvarez R; Cruz Jurado J; Del Muro Solans XG; Giner JL; López Pousa A; Martín-Broto J; Valverde CM.

Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus.

Sarcoma. 2019; 2019: 4351308-4351308 [doi:10.1155/2019/4351308]

Marquez-Rodas, I; Arance, A; Berrocal, A; Larios, CL; Curto-Garcia, J; Campos-Tapias, IX; Blanca, AB; Martin-Algarra, S.

A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

Clinical & Translational Oncology. 2019; 21(12): 1754-1762 Nº de citas: 1 [doi:10.1007/s12094-019-02201-z]

Metro, G; Addeo, A; Signorelli, D; Gili, A; Economopoulou, P; Roila, F; Banna, G; De Toma, A; Cobo, JR; Camerini, A; Christopoulou, A; Lo Russo, G; Banini, M; Galetta, D; Jimenez, B; Collazo-Lorduy, A; Calles, A; Baxevanos, P; Linardou, H; Kosmidis, P; Garassino, MC; Mountzios, G.

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort

Journal of Thoracic Disease. 2019; 11(12): 4972-4981 Nº de citas: 44 [doi:10.21037/jtd.2019.12.23]

Perez, EA; Barrios, C; Eiermann, W; Toi, M; Im, YH; Conte, P; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Petersen, JA; De Haas, S; Hoersch, S; Patre, M; Ellis, PA.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE

CANCER. 2019; 125(22): 3974-3984 Nº de citas: 94 [doi:10.1002/cncr.32392]

Hollern, DP; Xu, N; Thennavan, A; Glodowski, C; Garcia-Recio, S; Mott, KR; He, XP; Garay, JP; Carey-Ewend, K; Marron, D; Ford, J; Liu, SY; Vick, SC; Martin, M; Parker, JS; Vincent, BG; Serody, JS; Perou, CM.

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer

CELL. 2019; 179(5): 1191 Nº de citas: 387 [doi:10.1016/j.cell.2019.10.028]